PFE

figures

checks

• assets = liabilities + equity · total assets equals total liabilities and equity
• equity excludes minority interests · totalEquity excludes noncontrolling interests
• net income is before preferred dividends · net income is not the after-preferred-dividends line
• diluted EPS is for total net income · diluted EPS is for total net income
• net income excludes minority interests · netIncome excludes noncontrolling interests
• cash flows tie to the change in cash · operating + investing + financing = 49000000, but the printed net change in cash is 91000000

management's claims

trace

1. 0locator (code)0.25s

   {
     "tables": 264,
     "exhibits": [],
     "documents": 1
   }

   {
     "income": {
       "rows": 32,
       "scale": 1000000,
       "score": 51.25,
       "heading": "Consolidated Statements of Operations Pfizer Inc. and Subsidiary Companies",
       "tableIndex": 111,
       "runnerUpScore": 25.25
     },
     "balance": {
       "rows": 42,
       "scale": 1000000,
       "score": 54.5,
       "heading": "Consolidated Balance Sheets Pfizer Inc. and Subsidiary Companies",
       "tableIndex": 115,
       "runnerUpScore": 26.75
     },
     "cashflow": {
       "rows": 48,
       "scale": 1000000,
       "score": 55,
       "heading": "Consolidated Statements of Cash Flows Pfizer Inc. and Subsidiary Companies",
       "tableIndex": 119,
       "runnerUpScore": 16
     }
   }

2. 1income statement agent1.86s · 1699 tokens · $0.0002

   {
     "rows": 32,
     "retryHint": null,
     "tableIndex": 111
   }

   {
     "figures": [
       {
         "note": "Total revenues is the company-wide revenue line.",
         "field": "revenue",
         "scale": 1000000,
         "value": 62579000000,
         "printed": "62,579",
         "rowIndex": 6,
         "rowLabel": "Total revenues",
         "priorValue": 63627000000,
         "agentPrinted": "62,579",
         "failedChecks": [],
         "priorPrinted": "63,627",
         "groundingMismatch": false
       },
       {
         "note": "No operating income or equivalent line is printed; pretax income is not a substitute.",
         "field": "operatingIncome",
         "scale": 1000000,
         "value": null,
         "printed": null,
         "rowIndex": null,
         "rowLabel": null,
         "priorValue": null,
         "agentPrinted": null,
         "failedChecks": [],
         "priorPrinted": null,
         "groundingMismatch": false
       },
       {
         "note": "This is net income attributable to Pfizer Inc. common shareholders, excluding noncontrolling interests.",
         "field": "netIncome",
         "scale": 1000000,
         "value": 7771000000,
         "printed": "7,771",
         "rowIndex": 21,
         "rowLabel": "Net income attributable to Pfizer Inc. common shareholders",
         "priorValue": 8031000000,
         "agentPrinted": "7,771",
         "failedChecks": [],
         "priorPrinted": "8,031",
         "groundingMismatch": false
       },
       {
         "note": "This is total diluted EPS attributable to Pfizer Inc. common shareholders.",
         "field": "epsDiluted",
         "scale": 1,
         "value": 1.36,
         "printed": "1.36",
         "rowIndex": 29,
         "rowLabel": "Net income attributable to Pfizer Inc. common shareholders",
         "priorValue": 1.41,
         "agentPrinted": "1.36",
         "failedChecks": [],
         "priorPrinted": "1.41",
         "groundingMismatch": false
       }
     ],
     "statement": "income",
     "tableIndex": 111,
     "priorColumn": 1,
     "currentColumn": 0
   }

3. 2cash flow agent1.90s · 1803 tokens · $0.0002

   {
     "rows": 48,
     "retryHint": null,
     "tableIndex": 119
   }

   {
     "figures": [
       {
         "note": "This row is the operating activities section total, including changes in working capital.",
         "field": "operatingCashFlow",
         "scale": 1000000,
         "value": 11704000000,
         "printed": "11,704",
         "rowIndex": 21,
         "rowLabel": "Net cash provided by/(used in) operating activities",
         "priorValue": 12744000000,
         "agentPrinted": "11,704",
         "failedChecks": [],
         "priorPrinted": "12,744",
         "groundingMismatch": false
       },
       {
         "note": "This row prints the investing activities section total.",
         "field": "investingCashFlow",
         "scale": 1000000,
         "value": -1351000000,
         "printed": "(1,351)",
         "rowIndex": 32,
         "rowLabel": "Net cash provided by/(used in) investing activities",
         "priorValue": 2652000000,
         "agentPrinted": "(1,351)",
         "failedChecks": [],
         "priorPrinted": "2,652",
         "groundingMismatch": false
       },
       {
         "note": "This row prints the financing activities section total.",
         "field": "financingCashFlow",
         "scale": 1000000,
         "value": -10304000000,
         "printed": "(10,304)",
         "rowIndex": 41,
         "rowLabel": "Net cash provided by/(used in) financing activities",
         "priorValue": -17140000000,
         "agentPrinted": "(10,304)",
         "failedChecks": [],
         "priorPrinted": "(17,140)",
         "groundingMismatch": false
       }
     ],
     "statement": "cashflow",
     "tableIndex": 119,
     "priorColumn": 1,
     "currentColumn": 0
   }

4. 3balance sheet agent2.05s · 1554 tokens · $0.0002

   {
     "rows": 42,
     "retryHint": null,
     "tableIndex": 115
   }

   {
     "figures": [
       {
         "note": "This is the balance sheet’s cash and cash equivalents line.",
         "field": "cash",
         "scale": 1000000,
         "value": 1142000000,
         "printed": "1,142",
         "rowIndex": 3,
         "rowLabel": "Cash and cash equivalents",
         "priorValue": 1043000000,
         "agentPrinted": "1,142",
         "failedChecks": [],
         "priorPrinted": "1,043",
         "groundingMismatch": false
       },
       {
         "note": "This row prints total assets.",
         "field": "totalAssets",
         "scale": 1000000,
         "value": 208160000000,
         "printed": "208,160",
         "rowIndex": 16,
         "rowLabel": "Total assets",
         "priorValue": 213396000000,
         "agentPrinted": "208,160",
         "failedChecks": [],
         "priorPrinted": "213,396",
         "groundingMismatch": false
       },
       {
         "note": "This is the explicit total liabilities line, not total liabilities and equity.",
         "field": "totalLiabilities",
         "scale": 1000000,
         "value": 121385000000,
         "printed": "121,385",
         "rowIndex": 31,
         "rowLabel": "Total liabilities",
         "priorValue": 124899000000,
         "agentPrinted": "121,385",
         "failedChecks": [],
         "priorPrinted": "124,899",
         "groundingMismatch": false
       },
       {
         "note": "This is Pfizer Inc. shareholders’ equity, excluding noncontrolling interests.",
         "field": "totalEquity",
         "scale": 1000000,
         "value": 86476000000,
         "printed": "86,476",
         "rowIndex": 38,
         "rowLabel": "Total Pfizer Inc. shareholders’ equity",
         "priorValue": 88203000000,
         "agentPrinted": "86,476",
         "failedChecks": [],
         "priorPrinted": "88,203",
         "groundingMismatch": false
       }
     ],
     "statement": "balance",
     "tableIndex": 115,
     "priorColumn": 1,
     "currentColumn": 0
   }

5. 4reconciler (code)0.00s

   null

   [
     {
       "name": "balance_identity",
       "detail": "total assets equals total liabilities and equity",
       "fields": [
         "totalAssets"
       ],
       "passed": true,
       "skipped": false,
       "statement": "balance"
     },
     {
       "name": "totalEquity_attribution",
       "detail": "totalEquity excludes noncontrolling interests",
       "fields": [
         "totalEquity"
       ],
       "passed": true,
       "skipped": false,
       "statement": "balance"
     },
     {
       "name": "netIncome_before_preferred",
       "detail": "net income is not the after-preferred-dividends line",
       "fields": [
         "netIncome"
       ],
       "passed": true,
       "skipped": false,
       "statement": "income"
     },
     {
       "name": "epsDiluted_total",
       "detail": "diluted EPS is for total net income",
       "fields": [
         "epsDiluted"
       ],
       "passed": true,
       "skipped": false,
       "statement": "income"
     },
     {
       "name": "netIncome_attribution",
       "detail": "netIncome excludes noncontrolling interests",
       "fields": [
         "netIncome"
       ],
       "passed": true,
       "skipped": false,
       "statement": "income"
     },
     {
       "name": "cash_flow_tie",
       "detail": "operating + investing + financing = 49000000, but the printed net change in cash is 91000000",
       "fields": [
         "operatingCashFlow",
         "investingCashFlow",
         "financingCashFlow"
       ],
       "passed": false,
       "skipped": false,
       "statement": "cashflow"
     }
   ]

6. 5MD&A claims agent5.49s · 3857 tokens · $0.0007

   null

   [
     {
       "kind": "amount_change",
       "field": "revenue",
       "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
       "scope": "segment_or_non_gaap",
       "actual": null,
       "reason": "Total revenue: about a segment, region or non-GAAP measure, which the statements can't confirm",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "$1.0 billion",
       "tolerance": null,
       "quoteVerified": true
     },
     {
       "kind": "percent_change",
       "field": "revenue",
       "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
       "scope": "segment_or_non_gaap",
       "actual": null,
       "reason": "Total revenue: about a segment, region or non-GAAP measure, which the statements can't confirm",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "2%",
       "tolerance": null,
       "quoteVerified": true
     },
     {
       "kind": "current_value",
       "field": "revenue",
       "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
       "scope": "segment_or_non_gaap",
       "actual": null,
       "reason": "Total revenue: about a segment, region or non-GAAP measure, which the statements can't confirm",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "$62.6 billion",
       "tolerance": null,
       "quoteVerified": true
     },
     {
       "kind": "current_value",
       "field": "revenue",
       "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
       "scope": "segment_or_non_gaap",
       "actual": null,
       "reason": "Total revenue: about a segment, region or non-GAAP measure, which the statements can't confirm",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "$63.6 billion",
       "tolerance": null,
       "quoteVerified": true
     },
     {
       "kind": "amount_change",
       "field": "revenue",
       "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
       "scope": "segment_or_non_gaap",
       "actual": null,
       "reason": "Total revenue: about a segment, region or non-GAAP measure, which the statements can't confirm",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "$1.3 billion",
       "tolerance": null,
       "quoteVerified": true
     },
     {
       "kind": "percent_change",
       "field": "revenue",
       "quote": "Total revenues decreased $1.0 billion, or 2%, to $62.6 billion in 2025 from $63.6 billion in 2024, reflecting an operational decrease of $1.3 billion, or 2%, partially offset by a favorable impact of foreign exchange of $247 million.",
       "scope": "segment_or_non_gaap",
       "actual": null,
       "reason": "Total revenue: about a segment, region or non-GAAP measure, which the statements can't confirm",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "2%",
       "tolerance": null,
       "quoteVerified": true
     },
     {
       "kind": "percent_change",
       "field": "revenue",
       "quote": "Excluding contributions from Comirnaty and Paxlovid, Total revenues increased 6% operationally.",
       "scope": "segment_or_non_gaap",
       "actual": null,
       "reason": "Total revenue: about a segment, region or non-GAAP measure, which the statements can't confirm",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "6%",
       "tolerance": null,
       "quoteVerified": true
     },
     {
       "kind": "amount_change",
       "field": "revenue",
       "quote": "The decrease in Income from continuing operations before provision/(benefit) for taxes on income of $503 million, to $7.5 billion in 2025 from $8.0 billion in 2024, was primarily due to (i) higher intangible asset impairment charges in 2025, (ii) an increase in Acquired in-process research and development expenses, (iii) net losses on equity securities in 2025 versus net gains on equity securities in 2024 and (iv) lower revenues, partially offset by (v) decreases in Cost of Sales, SI&A, and Restructuring charges and certain acquisition-related costs , and (vi) net periodic benefit credits associated with pension and other postretirement plans incurred in 2025 versus net periodic benefit costs in 2024.",
       "scope": "consolidated",
       "actual": null,
       "reason": "Total revenue: the claim is about continuing operations, which this statement line doesn't separate",
       "claimed": null,
       "verdict": "not_checked",
       "asWritten": "$503 million",
       "tolerance": null,
       "quoteVerified": true
     }
   ]